Biocon Share News - Latest Updates, Live News & More

More news about Biocon

Biocon Q1 Results: Earnings call recording published for investors

Biocon Limited has released the audio and video recordings of its Q1 FY27 earnings call, held on August 06, 2026. The disclosure was made to BSE and NSE in compliance with SEBI LODR Regulation 30. Investors can access the recordings on the company’s website to review management’s discussion on financial performance and strategic outlook.

06Aug 26

Biocon Latest Results: Expects Syngene International to Perform Well Between October and March

Biocon has expressed a positive outlook for its subsidiary Syngene International, expecting the company to perform well between October and March. The statement underscores Biocon's confidence in Syngene International's operational momentum during the second half of the fiscal year. No additional financial metrics or detailed quarterly results were available in the source data to provide further context.

06Aug 26

Biocon Launches Yesafili in US, Eyes H2 Growth With Existing Contracts

Biocon Limited commenced US commercial sales of Yesafili (aflibercept-jbvf), an FDA-approved interchangeable biosimilar to Eylea 2 mg, on August 3, 2026, targeting an estimated 19.8 million Americans with AMD. In its concall update, management anticipated a strong start supported by existing contracts, projecting gradual market share increases and stronger growth in H2. The reference product aflibercept recorded sales of approximately $5.89 billion in 2023, underscoring the significant market opportunity.

06Aug 26

Biocon: GLP-1 Product Line Continues To Be A Major Growth Factor - Concall Update

Biocon has highlighted its GLP-1 product line as a major growth factor in its latest conference call update. The company's management drew attention to this segment as a key strategic focus area. The concall underscores the continued importance of the GLP-1 portfolio to Biocon's overall business performance.

06Aug 26

Biocon Expands Its Global Manufacturing Network To Strengthen Regional Supply In France, Portugal, Slovenia, And Spain

Biocon has expanded its global manufacturing network to strengthen regional supply across France, Portugal, Slovenia, and Spain. The move is aimed at enhancing supply chain resilience and improving product accessibility in key European markets. This expansion reflects the company's strategic intent to build a geographically diversified manufacturing presence. The development positions Biocon to better align with regional demand and distribution requirements across Europe.

29Jul 26

Biocon to announce Q1FY27 results on Aug 5

Biocon Limited will announce Q1FY27 results on August 5, 2026, followed by an earnings call on August 6. The trading window is closed until August 8 due to insider trading regulations.

29Jul 26

Biocon secures Health Canada approval for Yesintek autoinjector pen

Biocon secured Health Canada’s Notice of Compliance for Yesintek® ustekinumab autoinjector pen, available in 45 mg/0.05 mL and 90 mg/mL dosages. Approved on July 29, 2026, this new format complements existing prefilled syringes and IV solutions, providing patients with a convenient self-administration option for autoimmune diseases like psoriasis and Crohn’s disease. The move strengthens Biocon’s competitive position in the Canadian biosimilar market.

22Jul 26

Bobby Parikh ceases as Biocon Independent Director

Bobby Kanubhai Parikh ceased to be an Independent Director of Biocon Limited on July 22, 2026, after completing his second term. The Board acknowledged his contributions. The disclosure follows Regulation 30 of the SEBI Listing Regulations.

15Jul 26

Biocon Limited Schedules 48th Annual General Meeting for August 6, 2026; Reports Strong FY26 Performance

Biocon Limited has announced its 48th AGM for August 6, 2026 via VC/OAVM, with e-voting open from August 1 to August 5, 2026. Key agenda items include adoption of FY26 financial statements, declaration of a final dividend of ₹0.50 per equity share, re-appointment of Eric Vivek Mazumdar as Director, appointment of S.R. Batliboi & Associates LLP as new Statutory Auditors, and approval of the Biocon Unity Long Term Incentive Plan 2026 covering up to 4,35,00,000 equity shares. In FY26, Biocon reported consolidated operating revenue of ₹169,270 million (up 11% YoY), EBITDA of ₹37,978 million (up 25% on a like-to-like basis), and Net Profit of ₹3,856 million, alongside the completion of the full integration of Biocon Biologics Limited.

15Jul 26

DAM Capital Maintains Buy on Biocon at ₹495; Bernstein Holds Underperform at ₹326

DAM Capital has maintained a Buy rating on Biocon with a target price of ₹495, pointing to Mylan's exit as the removal of a key overhang and projecting a 15% revenue CAGR for FY26–28 with EBITDA margins of 26–27%, driven by biosimilar launches in H2FY27. Bernstein, however, retains an Underperform rating with a ₹326 target, citing high leverage, slow monetization of Biologics and Syngene investments, rising biosimilar competition, and succession concerns. The brokerage also estimates the $2 billion revenue milestone to be 4–5 years away, reflecting a fundamentally different assessment of the company's near-term outlook.

14Jul 26

Biocon Records ₹1819.34 Crore Block Trade on NSE for ~45483460 Shares at ₹400

Biocon recorded a large block trade on the NSE during the pre-open session, with approximately 45483460 shares transacted at ₹400 per share. The total deal value of the transaction stood at ₹1819.34 crore. Such sizable block deals are generally associated with institutional buying or selling activity and tend to attract significant attention from market participants.

09Jul 26

Biocon publishes Yesafili trial data confirming comparability to Eylea

Biocon announced the publication of pivotal clinical data from the Phase III INSIGHT trial in peer-reviewed journals, confirming that its aflibercept biosimilar MYL-1701P (Yesafili) demonstrates comparable safety, efficacy, and immunogenicity to reference Eylea. The studies, published on June 29, 2026, and May 18, 2026, support the product's use for diabetic macular edema and other retinal conditions ahead of its U.S. launch.

09Jul 26

Viatris-Owned Mylan Likely to Sell Part of Its 5.64% Stake in Biocon via Block Deals

Viatris-owned Mylan is reportedly planning to divest a portion of its 5.64% stake in Biocon through block deals, according to CNBCTV18. The transaction is expected soon, though the exact quantum of the stake to be sold and the transaction value have not been disclosed.

07Jul 26

Biocon announces final dividend of Re. 0.50 per share for FY26

Biocon has declared a final dividend of Re. 0.50 per share for FY 2025-26, with the record date set for July 03, 2026. The 48th AGM will be held on August 06, 2026, via video conferencing, featuring remote e-voting from August 01 to August 05, 2026.

25Jun 26

Indian Drugmakers Prepare For Keytruda Biosimilar Competition After Patent Expiration; Keytruda's Global Sales Projected At $31.7 Billion By 2025

Indian pharmaceutical companies Biocon, Zydus, and Dr Reddy's are preparing to enter the biosimilar market for Keytruda (pembrolizumab) following its patent expiration. Keytruda's global sales are projected at $31.7 billion by 2025, representing a major commercial opportunity for biosimilar developers. The move reflects a strategic push by Indian pharma players into the high-value oncology biologics segment, where competition is expected to intensify as multiple companies pursue biosimilar development programs for the blockbuster cancer immunotherapy drug.

25Jun 26

Biocon partner secures MYR 225m insulin tenders in Malaysia

Biocon Limited's partner Duopharma Biotech Berhad has won multiple insulin tenders from the Ministry of Health Malaysia valued at over MYR 225 million. The contracts include a three-year agreement for human insulin worth ~ MYR 155.27 million and two-year agreements for insulin glargine and insulin aspart. Biocon Sdn. Bhd. will supply the products from its Johor facility, which has invested over USD 600 million and serves over 450,000 patients.

23Jun 26

Biocon outlines TDS rates for FY26 final dividend of ₹0.50

Biocon Limited has communicated the Tax Deducted at Source (TDS) rates applicable to the final dividend of ₹0.50 per share for FY26, recommended by the Board and subject to shareholder approval at the AGM on August 6, 2026. The company specified TDS rates for various resident and non-resident categories under the Income Tax Act, 2025, noting that tax will be deducted at 20% for residents without a valid PAN or Aadhaar linkage. Shareholders must update KYC details and submit necessary documents like Form 121 and TRCs to KFin Technologies Limited by July 20, 2026, to ensure correct tax deduction and electronic dividend credit.

16Jun 26

Biocon promoter group declares no encumbrance on shares in FY26

Biocon Limited's promoter group and Persons Acting in Concert have declared that no shares held by them were encumbered directly or indirectly during the financial year ending March 31, 2026. The declaration was submitted in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This confirmation was communicated to the BSE and National Stock Exchange of India.

11Jun 26

Biocon Invests ₹5.48 Crore in Ampin Solar Power SPV to Boost Green Energy Use

Biocon Limited has invested ₹5,47,60,000 in Ampin C&I Power Twelve Private Limited, a solar power SPV, acquiring 54,76,000 equity shares at ₹10 each, representing a 37.77% undiluted stake expected to reduce to 15.91% on full dilution. AMPIN is setting up a 27.12 MW (DC) solar plant in Karnataka, supporting Biocon's decarbonization goals and captive power requirements under the Electricity Act.

09Jun 26

Biocon to host Macquarie's Healthcare Tour plant visit on June 11

Biocon Limited will host a plant visit for Macquarie's Healthcare Tour on June 11, 2026, in Bangalore, serving as a group interaction with analysts and institutional investors. The company stated that the schedule is subject to change due to exigencies on the part of investors or the company. The management confirmed that no unpublished price sensitive information (UPSI) will be disclosed during the meeting.

09Jun 26

Biocon approves CEO appointment and remuneration revisions

Biocon Limited shareholders approved ten resolutions via postal ballot, including the appointment of Shreehas Pradeep Tambe as CEO & MD and remuneration revisions for Kiran Mazumdar-Shaw. The voting, held from May 09 to June 07, 2026, saw 73.56% participation and approved the preferential issuance of equity shares and several director appointments.

02Jun 26

Biocon reduces net debt to EBITDA ratio by 1.6x

Biocon Limited reduced its net debt to EBITDA ratio by 1.6x following a strategic refinancing that lowered total debt to $1,348 million from $1,389 million. The new debt structure defers major maturities to FY28 and FY29, enhancing liquidity. Additionally, the company increased its stake in Biocon Biologics to 99.2% and completed major infrastructure investments.

31May 26

Biocon revises preferential issue price to ₹376.41 per share

Biocon Limited revised the pricing for its preferential issue to ₹376.41 per share, with a floor price of ₹373.08, following advice from NSE and BSE. The company will issue 87,86,362 shares to Biocon Biologics shareholders at a swap ratio of 0.76159. A corrigendum was dispatched on May 29, 2026, and advertised in newspapers on May 30, 2026, with voting concluding on June 07, 2026.

28May 26

Biocon to meet investors at Investec US Pharma event on June 3

Biocon announced that its management will meet analysts and institutional investors on June 3, 2026, at the Investec US Pharma & Healthcare Bus Tour in the USA. The company stated that no unpublished price sensitive information will be disclosed during the meeting, which is subject to change due to exigencies.

27May 26

Biocon Records Rs. 17.37 Crore Block Trade on NSE at Rs. 431.95 Per Share

Biocon recorded a block trade on the NSE involving approximately 402,121 shares at Rs. 431.95 per share. The total value of the transaction amounted to Rs. 17.37 crores. Block trades of this scale are typically associated with institutional-level participation and are executed to minimize market impact.

11May 26

Biocon Pharma Limited Receives Health Canada Approval for Micafungin for Injection, USP, 50 MG and 100 MG

Biocon Pharma Limited, a subsidiary of Biocon Limited, received Health Canada approval on May 11, 2026, for micafungin for injection, USP, 50 mg and 100 mg. The product is indicated for adults and children four months and older for the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections, esophageal candidiasis, and prophylaxis of Candida infections in hematopoietic stem cell transplant patients. The approval is set to further strengthen Biocon's integrated biosimilars and generics portfolio.

10May 26

Biocon Q4FY26 & FY26 Results: Revenue Up 10% YoY; Key Corporate Actions Approved

Biocon reported Q4FY26 operating revenue of Rs 4,517 Cr and FY26 revenue of Rs 16,927 Cr, both up ~10-13% YoY on an adjusted basis, with EBITDA margin expanding ~200 bps. The Board approved the acquisition of remaining ~2% BBL equity via share swap at Rs. 376.16/share, a final dividend of Re. 0.50/share, new auditors, and an LTIP. The audio and video recording of the Q4 FY26 Earnings Call held on May 08, 2026 has been made available pursuant to SEBI Regulation 30.

08May 26

Biocon Approves Preferential Allotment to Consolidate Stake in Biocon Biologics

Biocon has approved the acquisition of approximately 2% stake in Biocon Biologics from employees and other shareholders via a preferential allotment. The company will issue up to 87.9 lakh shares at ₹376.16 each, aggregating to approximately ₹330.7 crore. The transaction is subject to requisite approvals and is intended to consolidate Biocon's ownership in its subsidiary Biocon Biologics.

05May 26

Kiran Mazumdar-Shaw Names Niece Claire Mazumdaar as Her Successor at Biocon

Biocon founder Kiran Mazumdar-Shaw has named her niece Claire Mazumdaar as her successor, as reported by Reuters citing Fortune India. The announcement signals a planned leadership transition at the biopharmaceutical company. No further specifics regarding the timeline or scope of the transition were available in the source data.

05May 26

Biocon Anticipates Margin Pressure for Insulin Glargine

Biocon has signaled anticipated margin pressure for its Insulin Glargine product, as reported by NDTV. The disclosure highlights potential challenges in the profitability of this biosimilar within the company's portfolio. No specific financial figures or timeframes were included in the available source information.

01May 26

Biocon: U.S. FDA Completes Pre-License Inspection At Biosimilars Plant

Biocon Limited successfully completed a U.S. FDA Pre-License Inspection at its biosimilars manufacturing facility in Bengaluru from April 20-29, 2026. The inspection covered 3 biologics manufacturing units, 5 quality testing laboratories, and 2 warehouses. The FDA issued a Form 483 with five procedural observations, notably with no data integrity issues or repeat observations from previous inspections. The company filed an official statement with stock exchanges on April 30, 2026, and committed to addressing all observations through a comprehensive CAPA plan within the FDA's stipulated timeline.

29Apr 26

Biocon Limited Publishes Newspaper Advertisements for Second 100 Days Campaign 'Saksham Niveshak'

Biocon Limited published newspaper advertisements on April 28, 2026, in Financial Express and Vijayavani as part of the Second 100 Days Campaign 'Saksham Niveshak' launched by the IEPF Authority. The campaign aims to help shareholders update KYC and bank details to claim unpaid/unclaimed dividends before transfer to IEPF. The company has submitted advertisement copies to BSE and NSE under SEBI regulatory compliance requirements.

26Apr 26

Biocon Limited Board Meeting intimation for Q4FY26 under Regulation 29 scheduled on 2026-05-07

Biocon Limited has filed regulatory intimation under SEBI LODR Regulation 29(1) for board meeting on May 07, 2026 to approve audited Q4 and FY26 financial results. The company has implemented trading window closure from April 01-May 09, 2026 for insider trading compliance. An earnings conference call is scheduled for May 08, 2026 at 09:00 hrs IST via Zoom, with recordings and transcripts to be made available within specified timelines.

22Apr 26

Biocon Receives Health Canada Approval for Biosimilars Bosaya and Vevzuo

Biocon Limited announced Health Canada's approval of Bosaya™ and Vevzuo™, denosumab biosimilars for treating osteoporosis and cancer-related bone conditions. The approval covers multiple patient populations including postmenopausal women, men with osteoporosis, and cancer patients with bone metastases, potentially benefiting over 2 million adults with osteoporosis and hundreds with bone metastasis annually.

22Apr 26

Biocon Limited Issues KYC Compliance Reminder to Physical Shareholders Under SEBI Regulations

Biocon Limited has issued a compliance reminder to physical shareholders regarding mandatory KYC updates as per SEBI Master Circular dated February 06, 2026. The company warns that dividend payments may be withheld for non-compliant folios and has outlined specific documentation requirements including Form ISR-1 and Form ISR-2 submissions through multiple channels including courier, electronic mode, or web portal via registrar KFin Technologies Limited.

20Apr 26

HSBC Maintains Buy Rating on Biocon with ₹425 Target Price on Strong Growth Foundation

HSBC has reaffirmed its Buy rating on Biocon with a target price of ₹425, highlighting the company's strengthened foundation through debt reduction and corporate simplification. The investment bank identifies execution of new biosimilar launches, improving profitability metrics, enhanced cash flow generation, and market share gains in biosimilars as key growth catalysts for the biotechnology company.

08Apr 26

Biocon Limited Schedules Investor Meetings at HSBC Global Investment Summit 2026 and Singapore Roadshow

Biocon Limited has scheduled investor meetings at the HSBC Global Investment Summit 2026 in Hong Kong on April 14-15, 2026, and an investor roadshow in Singapore on April 16-17, 2026. The company will conduct one-on-one and group meetings with analysts and institutional investors while ensuring no unpublished price sensitive information is disclosed during these interactions.

08Apr 26

Biocon Limited Submits Q4 FY26 Certificate Under SEBI Depositories Regulations

Biocon Limited filed its mandatory quarterly certificate under SEBI Regulation 74(5) for Q4 FY26 on April 07, 2026, covering the quarter ended March 31, 2026. The certificate confirms compliance with dematerialization and rematerialization requirements, with registrar KFin Technologies Limited providing confirmation of proper handling of all demat processes including timely request processing and register maintenance.

08Apr 26

Biocon Announces U.S. Launch Of Bosaya™ And Aukelso™ Denosumab Biosimilars

Biocon Limited has commercially launched two denosumab biosimilars, Bosaya™ and Aukelso™, in the United States following FDA approval with interchangeable designation. These products target significant patient populations with osteoporosis and bone metastasis, entering a $5 billion market segment while expanding Biocon's biosimilars portfolio in oncology and immunology therapeutics.

07Apr 26

Biocon Ltd Records ₹47.97 Crore Block Trade on NSE at ₹349.00 Per Share

Biocon Ltd witnessed significant institutional trading activity with a block trade worth ₹47.97 crores on NSE. The transaction involved approximately 1,374,453 shares priced at ₹349.00 per share, reflecting routine institutional portfolio adjustments and demonstrating strong liquidity in the company's stock.